gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BMRAHealthcareDiagnostics

BIOMERICA INC (BMRA)

$1.74+2.06%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.74▼ 30.04% in range
Nov 4, 2025Low $1.49 · High $2.88Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

BIOMERICA closed at $1.74 on Nov 4, up 2.06%, 39.8% below its 52-week closing high. Volume of 12.1K shares was 1.20× its 20-day average (close to normal).

Split-adjusted performance: -18.9% over one month, -21.5% over six months, -36.0% over one year.

In the quarter ended Aug 31, 2026, revenue was $1.26M, down 8.3% from a year earlier, with a net margin of -97.4%.

Short interest was 10.5K shares at the Oct 15 settlement, down 62.1% from the prior report (0.3% of float, 1.0 days to cover).

Market cap$8.0M4.6M shares
Revenue · quarter$1.3M−8.3% YoY
Diluted EPS$-0.37—
P/E · TTM—P/S 1.8×
Net margin-97.4%Gross 8.1%
Dividend yieldNone
52-week range1.49 – 2.88−39.8% from high
Volume12.1K1.20× 20-day avg
Volatility · 60d71.8%Annualised
Short % of float0.3%1.0 days to cover
Net cash$2.7MCash $2.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.9%1M −18.9%3M +8.4%6M −21.5%YTD −31.2%1Y −36.0%3Y −77.1%5Y −95.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum21
Revenue growth42
Net margin42
Value (low P/E)—
Size21

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short10.5K−62.1% vs prior
Days to cover1.0Settled Oct 15
% of float0.3%
Short vol. 10d32.7%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BMRABIOMERICA$1.74+2.06%−21.5%−8.3%−97.4%—$8.0M
VNRXVolitionRx Limited$0.2031+5.23%−91.8%−2.0%−1953.1%—$6.1MCompare
CDIOCardio Diagnostics Holdings$1.65+2.81%−9.6%−28.3%−28012.5%—$4.9MCompare
QCLSQ/C Technologies$0.3910−8.00%−90.2%———$3.2MCompare
IMDXInsight Molecular Diagnostics$2.65−3.28%−47.3%−53.9%−4711.3%—$86.7MCompare
ICCCImmucell$10.37+1.17%+19.7%+11.5%25.5%119.6$94.2MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare

News about BIOMERICA

All news →

No recent articles focused on BIOMERICA.

Quick answers

What does BIOMERICA do?
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests.
What is BMRA's market cap?
$7.98M, based on the Nov 4 close of $1.74.
Does BIOMERICA pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BMRA is sold short?
10.5K shares, 0.3% of float, as of Oct 15, 2026.
What sector is BMRA in?
Healthcare, in the Diagnostics industry.

About BIOMERICA

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.

HQ: Irvine, CA50 employeesListed Sep 26, 1978biomerica.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology